Results 21 to 30 of about 15,930 (153)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.

PLoS ONE, 2019
The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer
Paiyun Li, Xuehong Zhang, Liankun Gu, Jing Zhou, Dajun Deng   +4 more
doaj   +1 more source

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance

Cancer Biology & Medicine, 2019
Objective Lack of effective therapies remains a problem in the treatment of oral squamous cell carcinoma (OSCC), especially in patients with advanced tumors.
Nur Syafinaz Zainal, Bernard Kok Bang Lee, Zheng Wei Wong, Iuan Sheau Chin, Pei San Yee, Chai Phei Gan, Kein Seong Mun, Zainal Ariff Abdul Rahman, J. Silvio Gutkind, Vyomesh Patel, Sok Ching Cheong   +10 more
doaj   +1 more source

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Patient Preference and Adherence, 2023
Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences,
Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X   +5 more
doaj  

Rational design of a lipophilic β-galactosidase-responsive near-infrared probe for in vivo imaging of cellular senescence. [PDF]

Smart Mol
We developed a lipophilic near‑infrared probe (DCIP‑AcGal) that is specifically activated by senescence‑associated β‑galactosidase. After intravenous injection, it lights up therapy‑induced tumor senescence in living mice. Its optimized lipophilicity also enables blood‑brain barrier crossing to detect natural brain senescence ex vivo. This probe offers
Huang J, Chu F, Feng B, Chen L, Cen P, Wang J, Qu Y, Hong L, Wu F, Tian H, Fang Y, Chen Y, Tian M, Zeng W, Zhang H, Zhong Y.   +15 more
europepmc   +2 more sources

Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling

Current Issues in Molecular Biology
Palbociclib is a cyclin-dependent kinase 4/6 inhibitor and a commonly used antitumor drug. Many cancers are susceptible to palbociclib resistance, however, the underlying metabolism mechanism and extent of resistance to palbociclib are unknown.
Lulu Yang, Yajun Yue, Zhendong Wang, You Jiang, Zhichao Xue, Yongzhuo Zhang   +5 more
doaj   +1 more source

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

Journal of Global Oncology, 2017
Purpose: To assess efficacy and safety of palbociclib plus fulvestrant in Asians with endocrine therapy–resistant metastatic breast cancer. Patients and Methods: The Palbociclib Ongoing Trials in the Management of Breast Cancer 3 (PALOMA-3) trial, a ...
Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Young-Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, Carla Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro   +14 more
doaj   +1 more source

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells

Cancer Cell International, 2020
Background Aberrant activity of cell cycle proteins is one of the key somatic events in non-small cell lung cancer (NSCLC) pathogenesis. In most NSCLC cases, the retinoblastoma protein tumor suppressor (RB) becomes inactivated via constitutive ...
Lindsey R. Conroy, Pawel Lorkiewicz, Liqing He, Xinmin Yin, Xiang Zhang, Shesh N. Rai, Brian F. Clem   +6 more
doaj   +1 more source

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older

Frontiers in Oncology, 2023
BackgroundElderly patients are generally underrepresented in oncology clinical trials; therefore, real-world data are needed to inform clinical management of elderly patients with hormone receptor–positive/human epidermal growth factor receptor 2 ...
Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Hope S. Rugo   +6 more
doaj   +1 more source

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study

BMC Cancer, 2022
Introduction Approximately 20–33% of all cancer patients are treated with acid-reducing agents (ARAs), most commonly proton pump inhibitors (PPIs), to reduce gastroesophageal reflux disease symptoms.
Kadir Eser, Arif Hakan Önder, Emel Sezer, Timuçin Çil, Ali İnal, Banu Öztürk, Vehbi Erçolak, Berna Bozkurt Duman, Halil Çelik, Tolga Köşeci, Oğuzhan Kesen   +10 more
doaj   +1 more source